Protara Therapeutics Inc Stock Price, News & Analysis

Protara Therapeutics (Nasdaq: TARA) announced management will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 10:00am ET. This virtual event will allow participants to gain insights into Protara's pipeline, including TARA-002, a cell-based therapy aimed at treating non-muscle invasive bladder cancer and lymphatic malformations.

The presentation will be available via webcast on the company's website, archived for 90 days for investor access.

Protara Therapeutics (Nasdaq: TARA) welcomed Dr. Jane Huang to its Board of Directors, bringing extensive experience in oncology drug development. Dr. Huang's leadership roles include Chief Medical Officer at BeiGene and key positions at Acerta Pharma and Genentech. The appointment aims to enhance Protara's progress in developing TARA-002, a therapy for non-muscle invasive bladder cancer and lymphatic malformations. This move is expected to strengthen Protara's strategic direction as they continue to advance their innovative therapies for cancer and rare diseases.

Protara Therapeutics (Nasdaq: TARA) has announced its participation in two significant virtual investor conferences. The first is the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021, at 11:35 AM ET, followed by the Jefferies Virtual Healthcare Conference on June 2, 2021, at 1:30 PM ET. Investors can access live webcasts of the presentations on the Company's website, which will be archived for 90 days. Protara focuses on developing therapies for cancer and rare diseases, including its lead program, TARA-002.

Protara Therapeutics (TARA) provided a business update and financial results for Q1 2021, highlighting strong cash reserves of $155 million as of March 31, 2021. The company is on track to file an Investigational New Drug (IND) application and initiate a Phase 1 trial for TARA-002 targeting non-muscle invasive bladder cancer (NMIBC) by year-end 2021. The research and development expenses rose 125% to $7 million due to costs related to TARA-002, while general administrative expenses decreased. Protara reported a net loss of $13.5 million or $1.20 per share.

Protara Therapeutics (Nasdaq: TARA) announced plans for an additional clinical study to support their Biologics License Application for TARA-002, targeting Lymphatic Malformations (LMs). Based on FDA feedback, the company will conduct large-scale GMP manufacturing comparability in late 2021 and initiate a pediatric clinical study pending alignment with the FDA. TARA-002 is derived from the same cell bank as OK-432, an approved treatment in Japan and Taiwan. Protara aims to deliver the first FDA-approved drug for LMs.

Protara Therapeutics (Nasdaq: TARA) has granted inducement non-qualified stock options for 120,000 shares to Dr. Martín Sebastian Olivo, the new Chief Medical Officer. The options have an exercise price of $15.30 per share, aligning with Protara's closing price as of April 19, 2021. Vesting occurs over four years, with 25% vesting after one year and the remainder vesting monthly. This award, approved by the Compensation Committee, aligns with NASDAQ Listing Rule 5635(c)(4). Protara is focused on developing therapies for cancer and rare diseases.

Protara Therapeutics, Inc. (Nasdaq: TARA) announced the immediate appointment of Dr. Martín Sebastian Olivo as Chief Medical Officer. With over 15 years in oncology research and global drug development, Dr. Olivo previously led clinical development for Gilead Sciences' breast cancer program. His expertise is expected to significantly impact Protara's lead product, TARA-002, for treating non-muscle invasive bladder cancer and lymphatic malformations. Dr. Olivo's experience is anticipated to enhance the company's strategic objectives in developing transformative therapies for cancer and rare diseases.

Protara Therapeutics (Nasdaq: TARA) announced significant advancements in its clinical pipeline, particularly for TARA-002 targeting non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Phase 1 study for NMIBC is expected to begin by year-end 2021, with cash reserves of $169M as of December 31, 2020. R&D expenses surged to $12M in 2020, reflecting growth in clinical programs. However, Protara reported a net loss of $34M, or $4.70 per share, for the year, compared to a $7.8M loss in 2019. The company remains optimistic about its future trajectory.

Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 10:00am ET. The event will be held virtually, and a live audio webcast will be accessible on the company's website. Protara focuses on developing transformative therapies for cancer and rare diseases, with lead programs including TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease.